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Abstract
Background: Malaria is a major public health threat in Africa, and traditional medicine continues to play a key role
in its control especially in rural areas. A bioassay-guided fractionation was carried out in order to evaluate the anti-
malarial potential and the safety of the methanol extract of the Hypericum lanceolatum stem bark.
Methods: The anti-plasmodial activity was assayed by the lactate dehydrogenase method (pLDH) against the
multidrug-resistant W2mef laboratory strain, and a field isolate (SHF4) of Plasmodium falciparum. Cytotoxicity tests
were carried out using the LLC-MK2 monkey kidney epithelial cells.
Results: Five compounds were isolated from the most active and least cytotoxic ethylacetate sub-extract: betulinic
acid (HLT1), 2,2’,5,6’-tetrahydroxybenzophenone (HLT2), 5-hydroxy-3-methoxyxanthone (HLT3), 3-hydroxy-5-
methoxyxanthone (HLT4) and HLT0 (yet to be identified). Three of the tested compounds presented significant
anti-plasmodial activities (with 50% inhibitory concentration, IC50 <5μM), with 5-hydroxy-3-methoxyxanthone
exerting the highest activity, followed by HLT0 and betulinic acid. All the compounds with significant anti-
plasmodial activity were non-cytotoxic, except betulinic acid which showed a 50% cytotoxic concentration, CC50 of
25 μg/mL.
Conclusions: These findings justify the use of H. lanceolatum stem bark as anti-malarial by traditional healers of
Western Cameroon, and could constitute a good basis for further studies towards development of new drug
candidates or phytomedicines for malaria.
Background
The fight against malaria was identified by the United
Nations in the Millennium Development Goals as an
objective and remains one of the priorities for the
World Health Organization. Chemotherapy is central to
any strategy for effective reduction of mortality related
to malaria, since an efficient vaccine is yet to be
approved [1]. The emergence and relentless spread of
resistance against all the drugs in current use, including
the newly introduced artemisinin-based combination
therapy, have aggravated the disease burden in endemic
regions [2,3]. Hence, there is an urgent need to discover
new efficacious and safe anti-malarial drugs in order to
face this situation.
For decades, traditional herbal medicine had consti-
tuted a good basis for anti-malarial lead discovery and
drug development. A typical example is quinine, which
was the first anti-malarial drug of plant source, isolated
from the bark of Cinchona tree (Rubiaceae) in 1820 [4].
Quinine is one of the oldest and most important anti-
malarial drugs, which remains a first line drug today for
the treatment of severe malaria. This molecule also
served as template for the synthesis of prominent chlor-
oquine and mefloquine [5]. More recently, artemisinin
isolated from the Chinese plant Artemisia annua, has
been used successfully against multidrug-resistant
strains of malaria parasites [6]. Previous investigations
showed that over 200 plants species were identified in
Cameroon for their use in malaria treatment by tradi-
tional healers, and some of these were proven to contain
active ingredients with significant anti-plasmodial
activity [7-9]. Hypericum lanceolatum also known as
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lata, Campylosporus angustifolius, Campylosporus
madagascariensis, Campylosporus reticulatus, Hypericum
angustifolium, Hypericum madagascariense, Hypericum
revolutum, is a multipurpose plant, commonly used in
Cameroon traditionally to treat several ailments includ-
ing malaria, skin infections, venereal diseases, gastroin-
testinal disorders, tumours, infertility and epilepsies [10].
The stem bark is usually boiled in water and adminis-
tered either as steam bath or orally for the treatment of
m a l a r i aa n do t h e rf e v e r s .T h er o o t sa r ea l s ok n o w nf o r
their use against intestinal worms and dysentery. They
are combined with Mangifera indica leaves, boiled and
administered as a drink. In the Lebialem Division (South
West Region), decoction of fresh leaves is taken orally to
treat nerves problems [10].
However, despite the endemic use of H. lanceolatum
as an anti-malarial herbal medicine in Cameroon, its
efficacy is yet to be experimentally established. A bioas-
say-guided fractionation of the stem bark of this plant
was conducted in order to assess the in vitro anti-plas-
modial activity, thus the potential of the plant species as
source of new malaria drug leads.
Methods
Collection of plant materials
Stem bark of H. lanceolatum was collected on the
Mount Bamboutos flanks (Western Region, Cameroon)
in May 2009. The sample identification was confirmed
by Mr. Victor Nana, botanist at the Cameroon National
Herbarium in Yaounde, where a voucher specimen was
deposited (Voucher No 32356/HNC).
Preparation of crude extract
The air-dried and powdered plant material (1.5 Kg) was
macerated for three days at room temperature in 5 L of
methanol, filtered with Whatman paper, and the solvent
evaporated using a Rotavapor system (BÜCHI Labor-
technik AG, Switzerland) to obtain a crude extract (170
g) which was stored at - 20°C till further use.
Bioassay-guided fractionation, isolation and
characterization of pure compounds
The fractionation as well as the purification and charac-
terization of isolated compounds were done as pre-
viously described by Tane et al [11]. Only extracts or
fractions with IC50 <1 0μg/mL and CC50 >3 0μg/mL
were considered for the further steps. An amount of 150
g of the MeOH extract was dissolved in 1 L of distilled
water and sequentially partitioned with n-hexane (5 L),
EtOAc (5 L), and n-BuOH (5 L) to give respective
extracts. All the three sub-extracts were screened for
their anti-plasmodial and cytotoxicity profiles and the
EtOAc sub-extract was retained for further investigation
provided its high activity and relative safety. An amount
of 45 g of this extract was subjected to a silica gel col-
umn chromatography eluted with gradients of n-hexane-
EtOAc (10:0; 9:1; 8:2; 1:1; 0:10) and EtOAc-MeOH (10:0;
9:1; 8:2; 1:1; 0:10). Twenty seven fractions of 500 mL
each were collected and combined on the basis of their
TLC profiles into five major fractions F1-F5 (F1: 1-5; F2:
6-7; F3: 8-12; F4: 13-21; F5: 22-27). Fraction F1 (3 g)
contained mostly mixture of sterols and was not consid-
ered for further investigation given the poor outcome of
the biological screening. Fraction F2 (4.5 g) was purified
on a silica gel column chromatography (50 mm × 600
mm), eluted with a gradient of n-hexane-EtOAc (100:0;
95:5; 90:10; 85:15; 80:20; 0:100), to give HLT1 (90 mg,
Rf = 0.48; n-hexane-EtOAc 80:20) and HLT2 (150 mg,
Rf = 0.5; n-hexane-EtOAc 95:5). Fraction F3 (10.6 g)
was submitted to a silica gel column chromatography
(50 mm × 600 mm), eluted with gradients of CH2Cl2-
EtOAc (100:0; 95:5; 90:10; 85:15; 80:20; 70:30, 0:100),
and EtOAc-MeOH (100:0; 95:5; 90:10), to yield HLT3 (9
mg, Rf = 0.28; n-hexane-EtOAc 60:40) and HLT0 (8 mg,
Rf = 0.32; n-hexane-EtOAc 60:40). Fraction F4 (12.8 g)
was chromatographed on a silica gel column with
n-hexane-EtOAc (100:0; 95:5; 90:10; 85:15; 80:20; 0:100)
and EtOAc-MeOH (100:0; 95:5; 90:10; 85:15; 80:20;
70:30, 0:100). Sub-fractions eluted by n-hexane-EtOAc
(8:2) were further purified on Sephadex LH-20 using
CH2Cl2-MeOH (1:1) to give HLT4 (30 mg, Rf = 0.40;
n-hexane-EtOAc 60:40).
The structures of the isolated compounds were eluci-
dated using spectroscopic methods and comparison
done with published data. Melting points (uncorr.) were
recorded on a Reichter microscope or on a Büchi melt-
ing point B-540 apparatus. The IR and UV spectra were
recorded on a Shimadzu FTIR-84000S spectrophot-
ometer and a Jasco V-550 UV/Vis spectrophotometer,
respectively.
1HN M Ra n d
13C NMR spectra were
recorded on Joel JNM ECA-600 and AL-400 spectro-
meters. Chemical shifts (δ) were reported in parts per
million (ppm) with the residual solvent signals as inter-
nal reference. Coupling constants (J values) were given
in Hertz. Column chromatography was run with Merck
silica gel 60 and Sephadex LH-20. Analytical TLC was
carried out on silica gel (Merck GF254) precoated plates
with spots detected with an UV lamp at 254 and 366
nm and further visualized by spraying with 50% H2SO4,
followed by heating at 100°C.
Parasite strain
The W2mef (MRA-615) strain was ordered from the
Malaria Research and Reference Reagent Resource Cen-
tre (MR4, Manassas, VA, USA), and maintained in con-
tinuous culture. The SHF4 field isolate previously
isolated from a malaria patient in Buea in the South
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nitrogen at the Biotechnology Unit, University of Buea.
Plasmodium falciparum culture and maintenance
The field isolate and the laboratory strain of P. falci-
parum were grown and maintained in culture using the
method of Trager and Jensen with some modification
[8,9,12]. All the chemicals except Albumax II (Gibco;
Invitrogen, USA), were ordered from Sigma-Aldrich Inc
(Germany). Cultures consisted of a 4% haematocrit sus-
pension of O+ human erythrocytes in RPMI 1640 med-
ium supplemented with a gentamicin solution at 0.01
mg/mL, 25 mM HEPES buffer, 25 mM NaHCO3,a n d
1% Albumax II. Cultures were fed with a gas mixture
consisting of 5% CO2 and incubated at 37°C (CO2 incu-
bator Heraeus, Hera cell 150; USA). The estimation of
the parasitaemia as well as parasite visualization before
incubation was done using both fluorescence (Acridine
Orange) and normal light (Giemsa stain) microscopes.
Determination of in vitro anti-plasmodial activity
The drug sensitivity assay was carried out in 96-well
microtitration plates as described by Desjardins et al
with some modifications [8,13]. All stock solutions were
sterilized by passing them through a 0.2 μms y r i n g ef i l -
ter and stored at -20°C until required. Similarly, a 2 μg/
mL stock solution of quinine dihydrochloride (Rotexme-
dica, Trittau, Germany) was prepared and used as posi-
tive control. The parasitaemia was measured using the
parasite lactate dehydrogenase (pLDH) assay.
Analysis of test results from the pLDH assay
The pLDH assay generates optical density (OD) values at
various concentrations of the drug as raw data. OD
values from control wells represent the maximum
amount of pLDH produced by parasites and OD values
from blank wells (containing a 4% suspension of non
parasitized red blood cells in malaria culture medium)
represented background pLDH activity. A 100% growth
value, which corresponds to maximum LDH activity, was
obtained by subtracting the mean OD value of blank
wells from that of control wells. Likewise, the growth
value at each concentration of the drug was obtained by
adjusting OD values from drug-treated wells for back-
ground pLDH activity (parasite-free red blood cells).
These values were then expressed as a percentage of the
maximal growth value and plotted against corresponding
concentrations of the drug using the software HN-Non-
Lin V1.1 [14] to generate log dose-response curves from
which the 50%, 90%, 95% and 99% Inhibitory Concentra-
tions (IC50,I C 90,I C 95 and IC99 respectively) were
obtained. Each product was tested in triplicate in each of
the two separate experiments, giving a total of six repeats
per product and per concentration tested. The IC50
values obtained from these replicates were pooled and
expressed as geometric mean IC50 values and the differ-
ent means compared among themselves by independent
samples t-test using SPSS Statistics 17.0 (Chicago, USA).
Cytotoxicity study of active compounds and extracts
The cytotoxicity profiles of the extracts and pure com-
pounds were estimated against LLC-MK2 monkey kidney
epithelial cells according to the procedure previously
described [14] with some modifications [9]. Cells were
cultured under the same conditions as P. falciparum.
Cells were distributed in 96-well plates at 20,000 cells per
well in 100 μL culture medium, and allowed to attach
and become confluent, for 24h. The medium was then
removed completely the next day and 100 μLo ff r e s h
medium was added to all the wells, followed by 100 μL
of crude extract (1000 μg/mL) or pure compounds (200
μg/mL) added in triplicate in row H. A two folds serial
dilution was made upward to obtain concentration range
of 250 - 3.90 μg/ml (crude extract) or 50 - 0.78 μg/ml
(pure compounds), cells at row A serving as control with-
out drug. The plates were incubated for five days at 37°C
in 5% CO2 in air. Cells concentration and viability in the
presence of extracts or pure compounds were compared
with that of control cultures without extracts. The defini-
tion of the cytotoxicity used [15] was: CC50 <1 . 0μg/ml
(high cytotoxicity); CC50 1.0 -10.0 μg/ml (moderate);
CC50 10.0-30.0 μg/ml (mild); and CC50 >3 0μg/ml (non
toxic). The selectivity index defined as SI = CC50/IC50
was also considered with a product considered cytotoxic
when SI < 10 [16].
Results
Anti-plasmodial activity and cytotoxicity of sub-extracts
and fractions from H. lanceolatum
The anti-plasmodial activity and cytotoxicity profiles of the
sub-extracts and fractions from H. lanceolatum extract are
summarized in Table 1. The ethylacetate sub-extract
showed a good activity (IC50 <1 0μg/mL) against W2mef
strain of P. falciparum, while the two other sub-extracts
exhibited weaker activities. None of the three sub-extracts
was significantly cytotoxic (CC50 >3 0μg/mL).
The fractionation of the most active ethylacetate sub-
extract yielded five major fractions that were also
screened against W2mef, with F3 exhibiting the highest
activity, followed by F4, F2; whereas fractions F1 and F5
showed weak activity. Except fraction F4 which with a
CC50 slightly below the 30 μg/mL cut off point, none of
the fractions showed significant cytotoxicity.
Description of the compounds isolated from Hypericum
lanceolatum
The structures of the compounds isolated are shown in
the Figure 1. The purification of fraction F2 led to
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pound HLT1 was obtained as colourless needles from
hexane-EtOAc, with a melting point of 319-320°C. It
reacted positively to the Liebermann-Burchard test,
which is characteristic of triterpenes. Its molecular for-
mula was determined as C30H48O3 and the molecular
weight was 456. HLT2 was obtained as yellow needles
and had a melting point of 201-202°C. It reacted posi-
tively to FeCl3 reagent, suggesting the presence of pheno-
lic hydroxyl group in the molecule. Its molecular formula
C13H10O5, corresponding to a molecular weight of 246.
Fraction F3 led to the isolation of HLT0 and HLT3.
Compound HLT0 appears as yellow powder. HLT3 was
equally obtained as yellowish powder having 166-168°C
as melting point. It reacted positively to FeCl3 reagent,
suggesting the presence of phenolic hydroxyl group in
the molecule. The molecular formula was determined as
C14H10O4 with a molecular weight of 242. Purification
of fraction F4 yielded one compound codified as HLT4.
This appeared as a yellowish powder from CH2Cl2,w i t h
melting point 284-285°C. It reacted positively to FeCl3
reagent, suggesting the presence of phenol-hydroxyl
group in its structure. The molecular formula was deter-
mined as C14H10O4 and the molecular weight was 242.
Extraction yield and anti-plasmodial activity of the pure
compounds of Hypericum lanceolatum
The extraction yield and anti-plasmodial activity of com-
pounds isolated from the ethylacetate sub-extract of H.
lanceolatum are presented in Table 2. Among the five
compounds isolated, HLT2 had the highest extraction
yield (3.33% of the dry fraction), followed by HLT1
whereas HLT3 showed the lowest yield (0.08%). Three of
the five compounds tested showed good anti-plasmodial
Table 1 Anti-plasmodial activity and cytotoxicity of sub-extracts and fractions from H. lanceolatum
Sub-extract or Fraction IC50 on W2mef (μg/mL) CC50 on LLC-MK2 cells (μg/mL) Selectivity Index (SI)
MeOH crude extract 3.98 ± 0.11 > 1000 -
Ethylacetate sub-extract 5.02 ± 1.01 204.86 ± 2.00 40.80 ± 0.39
Aqueous sub-extract 15.48 ± 6.25 125 ± 0.00 8.07 ± 0.00
n-butanol extract 11.95 ± 5.81 >1000 -
F1 15.60 ± 1.35 46.87 ± 15.62 3.00 ± 1.00
F2 6.37 ± 2.17 125 ± 0.00 19.62 ± 0.00
F3 3.91 ± 0.01 250 ± 0.00 39.24 ± 0.00
F4 5.33 ± 2.47 31.25 ± 0.00 5.86 ± 0.00
F5 14.52 ± 0.46 >1000 -
QN 0.27 ± 0.04 --
QN: Quinine
HO
COOH
HLT1
OH
OH
OH
O OH
HLT2
O
OH
H3CO
O
O
OCH3
HO
O
HLT3 HLT4
Figure 1 Structure of the compounds isolated from the ethylacetate sub-extract of H. lanceolatum stem bark.
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resistant W2mef parasite strain, with IC50 values below
5 μg/mL; all the remaining ones being weakly active
(IC50 >1 0μg/mL) on both W2-mef and field isolate
SHF4.
Cytotoxicity of the tested products on LLC-MK2 monkey
kidney epithelial cells
Table 3 presents the result of the cytotoxicity of the
tested compounds against the LLC-MK2 cells. Two out
of the 5 compounds were significantly cytotoxic (CC50 >
30 μg/mL) while one presented a low toxicity and the
remaining three were non toxic.
Discussion
From the MeOH crude extract prepared from the stem
bark of H. lanceolatum, three sub-extracts were
obtained and screened both for anti-plasmodial activity
against the multidrug-resistant W2mef strain of P. falci-
parum, and cytotoxicity on the LLC-MK2 monkey kid-
ney epithelial cells. The ethylacetate sub-extract was
shown to be the most active, followed by the n-butanol
whereas the water sub-extract was least active. In its tra-
ditional use in Western Cameroon, the stem bark is
boiled in water and administered as a tea, either alone
or in combination with other plants. The low activity of
the water soluble portion of the extract therefore shows
that the use of water as solvent may not be appropriate
for H. lanceolatum stem bark in the treatment of
malaria. This finding instead predicts the low polarity of
the active ingredients of the plant part. The activities of
the different sub-extracts were lower than the one of
the main methanol crude extract; this observation may
be an indication of synergistic interactions among the
compounds found in the main extract.
The fractionation of the most active sub-extract led to
five main fractions among which three were retained for
further purification based on their anti-malarial potential
and relative safety. The purification of the three active
fractions yielded five compounds. Four of these com-
pounds are well-known and two of them had been iso-
lated from other plant species, while two were previously
obtained by synthesis; none of them was known before as
occurring in H. lanceolatum.
From its spectral data, HLT1 was identified to be 3-
hydroxy-lup-20(29)-en-28-oic acid commonly known as
betulinic acid, a naturally occurring pentacyclic triterpe-
noid found in the bark of several plants species, princi-
pally the white birch (Betula pubescens)f r o mw h i c hi t s
name derives, but it was also isolated from Lycopus luci-
dus, Ziziphus mauritiana, Prunella vulgaris, the tropical
carnivorous plants Triphyophyllum peltatum and Ancis-
trocladus heyneanus, Diospyros leucomelas, Tetracera
boiviniana, the jambul Syzygium formosanum [17,18].
Betulinic acid was also directly synthesized from betulin,
which is an abundant compound of white birch, Betula
alba [19].
HLT2 was identified as 2,2’,5,6’-tetrahydroxybenzophe-
none, a compound that was previously synthesized in
1982 by Suzuki et collaborators from Matsushita Electric
Industrial Co., Ltd., an Osaka-based Japanese company,
and registered under the USA Patent number 4425404
[20]. Similarly, HLT3 identified as 5-hydroxy-3-methox-
yxanthone was described by Pedro et al in 2002 [21].
HLT4 which was identified to be the 3-hydroxy-5-meth-
oxyxanthone has equally been synthesized from a nat-
ural xanthone template by Gnerre et al [22].
The anti-plasmodial activities of the isolated products
were 3.26 - 55.12 μM against multidrug-resistant
W2mef laboratory strain, and 1.43 - 34.09 μMa g a i n s t
the SHF4 field isolate, with three compounds having
good activity. These are 5-hydroxy-3-methoxyxanthone,
betulinic acid and HLT0.
5-Hydroxy-3-methoxy-xanthone (HLT3) scored the
highest in vitro activity among the compounds tested.
Several xanthones of plant source have been reported
for their anti-malarial activity. The ethanol extract of
the bark of Garcinia dulcis (Guttiferae) furnished five
xanthones among which garciniaxanthone showed the
highest inhibitory effects on the growth of P. falciparum
with IC50 value of 0.96 μg/mL [23]. Anti-malarial
xanthones were equally isolated from Vriesea sanguino-
lent leaves (6-hydroxyluteolin-7-O-(1
2-a-rhamnoside,
IC50 =2 . 1 3μg/mL against K1) and Andira inermis
Table 2 Extraction yield and anti-plasmodial activity of pure compounds isolated from H. lanceolatum
Compound (code) Quantity (mg) Extraction yield IC50 on W2mef (μM) IC50 on SHF4 (μM)
HLT0 8 0.07 4.26 ± 0.15* 5.89 ± 0.20*
Betulinic acid (HLT1) 90 2.0 4.50 ± 1.35 5.60 ± 0.13
2,2’,5,6’-Tetrahydroxybenzophenone (HLT2) 150 3.33 55.12 ± 0.93 13.41 ± 0.16
5-Hydroxy-3-methoxyxanthone (HLT3) 9 0.06 3.26 ± 0.08 1.43 ± 0.48
3-Hydroxy-5-methoxyxanthone (HLT4) 30 0.11 33.84 ± 0.20 34.09 ± 0.12
QN -- 0.27 ± 0.04 0.14 ± 0.05
*IC50 expressed in μg/mL; Extraction yield expressed in % weight/weight of the ethylacetate fraction
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[5]. However, the anti-plasmodial activity of 5-hydroxy-
3-methoxyxanthone has not been documented. The iso-
mer of this compound, 3-hydroxy-5-methoxyxanthone,
also isolated from the same sub-extract of H. lanceola-
tum stem bark, was inactive both against W2mef and
the field isolate of the malaria parasite. This observation
suggests a key role played by the 5-hydroxyl group and/
or 3-methoxyl group in the mechanism of action of the
molecule. Further investigations including structure-
activity relationship study are necessary for a full under-
standing of the mechanism of action of the 5-hydroxy-
3-methoxyxanthone, and optimization of this hit into a
malaria drug candidate.
Betulinic acid is a multipotential molecule with anti-
inflammatory, anti-tumour, anti-angiogenesis, anti-neo-
plastic [24-27] and anti-viral anti-HIV activities [28,29].
The anti-plasmodial potential of this molecule was
equally established by previous studies. The molecule
isolated from the root bark of the Tanzanian species
Uapaca nitida was screened for its in vitro anti-plasmo-
dial activity of against CQ-resistant K1 and CQ-sensitive
T9-96 P. falciparum and exhibited a weak activity
against both strains, with IC50 of 19.6 and 25.9 μg/mL,
respectively [30,31]. Betulinic acid was equally isolated
from the Cameroonian plant Psorospermum glaberri-
mum and tested for its activity against the W2 strain of
P. falciparum,w i t ha nI C 50 of 5.10 μMw h i c hi ss i m i l a r
to the value of 4.50 μM obtained in this study with the
W2mef clone. These results, therefore, confirm the anti-
plasmodial potential of this molecule [32].
The methanol crude extract of H. lanceolatum showed
no sign of cytotoxicity against LLC-MK2 cells, even at
250 μg/mL. However, the aqueous sub-extract deriving
from this was slightly cytotoxic at high concentrations,
although the toxicity level was not considerable (CC50 >
30 μg/mL). Out of the five compounds isolated and
tested, only betulinic acid and 3-hydroxy-5-methoxyx-
anthone were mildly cytotoxic (10 ≤ CC50 ≤ 30 μg/mL).
Zuco et al [17] studied the in vitro cytotoxicity of betu-
linic acid in melanoma and non-melanoma tumour cell
lines. Betulinic acid exerted its anti-proliferative activity
on all the tested lines in a very narrow range of doses
(1.5 - 4.5 mg/mL), and was effective against wild-type
p53 and mutant p53 neoplastic cell lines derived from
cancers clinically resistant to conventional anti-neoplas-
tic drugs. However, the activity observed was selective
of tumour cells, as the compound showed no significant
cytotoxic activity against neural cells in vitro [17,33].
Cytotoxicity of several xanthones has been fully docu-
mented [34,35]. The present findings therefore corrobo-
rate the previous results.
In conclusion, the study shows that the ethylacetate
extract of H. lanceolaum stem bark has a higher anti-
malarial activity and least cytotoxicity, compared to the
n-butanol and water extracts. The use of medium polar
solvent in the preparation of natural medicine is therefore
recommended. This extract contains ingredients with dif-
ferent levels of anti-plasmodial activity, 5-hydroxy-3-
methoxyxanthone, the known betulinic acid and HLT0
being the most prominent compounds. These findings
therefore justify the use of stem bark of H. lanceolatum
in Cameroonian folk medicine for the treatment of
malaria. Further work including in vivo anti-malarial and
toxicity testing, are likely to yield new anti-malarial drug
candidates. Equally, the standardization of the extracts
could lead to effective phytomedicines which could be
locally exploited for the good of the populations who
may be unable to afford standard pharmaceutical drugs.
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